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Bullous eruption on the posterior thigh 
James Studdiford, MD; Amber Stonehouse, MD  
Thomas Jefferson University Hospital, Department of Family and Community 
Medicine, Philadelphia, Pa 
A healthy 11-year-old girl visited her family physician with a lesion on her right posterior 
thigh. The lesion was a 1-cm plaque that was tender, firm, erythematous, and indurated, 
with a central pustule. It had been present for 3 days; it was noticed by the patient after 
returning from a camping trip in southeastern Pennsylvania. The pustular area was 
incised, drained, and cultured, and the patient was started on cephalexin. 
Two days later, the lesion did not improve, showing increased induration, erythema, and 
blistering. The patient went to the emergency department with an 8 cm by 6 cm 
coalescence of thin-walled vesicles and bullae with surrounding erythema (FIGURES 1 
AND 2). A thick, honey-yellow adherent crust covered the eroded center of the lesion. 
The girl’s temperature was 37.1°C, and she reported no burning, pain, or pruritus. She 
had full range of motion of her right hip and knee, and no lymphadenopathy was 
detected. Her white blood cell count was normal; blood and wound cultures were taken. 
 
FIGURE 1  
Bullous eruption on the thigh 
 
Large coalescence of thin-walled bullae on an 
erythematous base located on the right posterior 
thigh. 
FIGURE 2  
Close-up 
 
Large coalescence of thin-walled bullae with a thick, 
honey-yellow adherent crust covering the eroded center 
of the lesion. 
 What is the most likely diagnosis? 
 How would you empirically treat this condition? 
 Diagnosis: Bullous impetigo, caused by methicillinresistant S aureus 
Impetigo is a highly contagious superficial skin infection, with peak incidence among 
children aged 2 to 6 years.1,2 Nonbullous impetigo (70% of cases) is caused by 
Staphylococcus aureus or betahemolytic Streptococcus.3  Bullous impetigo is almost 
always caused by S aureus. Epidermolytic toxins produced by phage group II strains 
cause loss of cell adhesion in the stratum granulosum due to proteolytic attack of 
desmoglein 1, resulting in bullae.4 
Bullous impetigo may occur after minor skin injury, such as an insect bite, abrasion, or 
dermatitis.  
Lesions generally start as small vesicles on the face, buttocks, extremities, or perineum, 
and may progress to a coalescence of thin-roofed bullae. The flaccid bullae rupture 
easily, draining serous or purulent fluid. 
Lesions are usually painless, and systemic findings are rare. Lymphadenopathy is rare in 
bullous impetigo but common in nonbullous impetigo. The disease is generally self-
limited and complications are uncommon. However, ecthyma (ulcerative impetigo) may 
result from an untreated impetigo infection.5 
Differential diagnosis 
The differential diagnosis for bullous impetigo is broad, and may include allergic contact 
dermatitis, herpes simplex, herpes zoster, pemphigus foliaceus, bullous pemphigoid, 
pemphigus vulgaris, and (in this case specifically) erythema migrans. 
Allergic contact dermatitis is a delayed hypersensitivity reaction, usually caused by skin 
contact with an allergen. Lesions can be vesicular, edematous, erythematous, and pruritic. 
In this case, the patient did not have allergen exposure or a pruritic lesion. 
Herpes zoster is a reactivation of the varicella zoster virus, characterized by stabbing, 
neuritic pain in a dermatomal distribution. Clear vesicles on an erythematous, edematous 
base distributed along a dermatome constitutes the classic appearance. This was not the 
case with this patient. 
Pemphigus foliaceous is an autoimmune intraepidermal blistering disease with lesions 
occurring on the face, scalp, chest, and upper back.5 Intact blisters are not commonly 
seen. The vesicle roof is very thin and ruptures easily, forming broad areas of crust. Skin 
biopsy reveals intraepidermal bulla or acantholysis in the upper epidermis. 
Pemphigus vulgaris is also an autoimmune blistering disease that affects the skin and 
mucous membranes. It is generally seen among patients aged >40 years. 
Bullous pemphigoid is an autoimmune disorder presenting with chronic eruption of 
erythematous, papular, urticaria lesions often evolving into bullae. Childhood cases are 
rare. Biopsy of the lesions demonstrates subepidermal bulla with an infiltration of 
eosinophils within the dermis.5 
Erythema migrans with central vesiculation must be considered given the patient’s 
camping trip. Recent evidence shows that erythema migrans with central redness 
accounts for most cases in areas endemic for Lyme disease. Only 10% of the patients 
with early Lyme disease show the classic bulls-eye lesion with concentric erythematous 
rings and central clearing. Vesiculation can occur in up to 30% of lesions.6 
Staphylococcus aureus and antibiotic resistance 
As many as 61% of community-acquired methicillin-resistant S aureus (MRSA) 
infections are initially treated only with beta-lactam antibiotics, to which they are 
resistant.7 Risk factors for community-acquired MRSA infection include day-care 
attendance, recent hospitalization, recent antibiotic use, chronic illness, and frequent 
health care visits.8 A growing number of cases are reported among patients without risk 
factors. 
Community-acquired MRSA isolates are usually genetically different from nosocomial 
isolates, and have been relatively susceptible to non–beta-lactam antibiotics. These 
strains vary substantially, however, and it is important to check the susceptibility of the 
isolate. 
Virulent new strains of S aureus are infecting children—these strains have a novel 
transpeptidase, which offers them a mechanism of resistance to beta-lactams different 
from hospital-and community-acquired types. 
Awareness of the local antimicrobial susceptibility patterns of community S aureus 
isolates is also helpful. Oral antibiotics that have been successful include clindamycin, 
minocycline, doxycycline, and trimethoprim-sulfamethoxazole. Cephalexin has no 
therapeutic value in treating community-acquired MRSA. 
Preventing disease spread in the patient and contacts 
Preventive efforts should be directed at patients with recurrent episodes of MRSA skin 
abscesses. Metabolic and immunologic screening should be performed to rule out 
underlying disease processes causing increased risk for infection. In most cases these test 
results are normal, and patients with recurrent MRSA skin abscesses should also be 
empirically treated for presumed nasal carriage of MRSA. 
Mupirocin ointment (Bactroban) should be applied to the nares twice daily for 5 days in 
an effort to prevent recurrent self-inoculation and lateral transmission of MRSA. 
Patients and families should also be instructed in hygienic measures such as daily 
changing of underwear and personal use only of towels, washcloths, and sleepwear. 
Fingernails should be kept short and clean. Open insect bites or superficial skin abrasions 
should be kept clean and covered. Benefit from the daily use of antimicrobial soaps is 
controversial. 
Empiric treatment of impetigo: Consider a culture for MRSA 
For localized impetigo, topical therapy with mupirocin 2% ointment 3 times a day for 10 
days is usually adequate. A 10-day course of oral antibiotic therapy with dicloxacillin or 
cephalexin is indicated in more widespread impetigo presumed to be methicillin-sensitive 
S aureus. Azithromycin (Zithromax) or clarithromycin (Biaxin) may be given to patients 
allergic to penicillin. 
However, it is becoming increasingly important to consider community-acquired 
methicillin-resistant S aureus species in cases such as this that do not respond to 
traditional therapy. Hence, culture and sensitivity of all suspicious lesions is highly 
suggested. 
Patient’s treatment and recovery 
In this case, the patient was diagnosed with bullous impetigo and admitted to the hospital. 
She was started on intravenous clindamycin at 380 mg (30 mg/kg) every 8 hours. 
Clindamycin was chosen because most cases of community-acquired MRSA in this 
geographic area are resistant to trimethoprim-sulfamethoxazole and susceptible to 
clindamycin. 
Although doxycycline would have covered both community-acquired MRSA and Lyme 
disease, we were less suspicious of Lyme given the physical exam of the patient, and we 
were reluctant to start this patient on doxycycline due to the fact she did not have 
complete maturation of her dentition.   
Within 24 hours of intravenous clindamycin, the lesion was markedly improved and the 
culture confirmed that the MRSA was sensitive to clindamycin. She was discharged on 
oral clindamycin at 375 mg 3 times daily, to complete a 14-day course of therapy. The 
lesion was completely resolved without recurrence within 2 weeks. 
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